ALZHEIMER'S DISEASE ADCS COOPERATIVE STUDY

VIVA MIND

vivoryon therapeutics

The VIVA-MIND trial is designed to determine if the study drug, varoglutamstat, can stabilize or slow memory and thinking problems that increase in early AD.

The VIVA-MIND clinical research trial is designed specifically for people who are age 50-89, and experiencing significant memory concerns, or who have already been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD). This stage of the disease, MCI through mild AD disease, is also known as early AD.

Basic Eligibility Criteria

- Age 50-89
- Diagnosed Mild Cognitive Impairment (MCI) due to AD or probable Mild AD
- Taking the following Alzheimer's medication(s) for at least four months: Donepezil (Aricept®) or rivastigmine (Exelon®) or galantamine (Razadyne®) with or without memantine (Namenda®)
- Have a study partner who can accompany the participant to clinic visits
- Willing to participate in the VIVA-MIND study for up to 20 months

What happens during the VIVA-MIND Study?

Participation in the study will take up to 20 months. A potential participant will first go through a screening process to see if they are eligible to take part in the clinical trial. Half of the participants are given the study drug, Varoglutamstat, and half are given an inactive pill (called a placebo), which is taken orally two times daily.

Screenings include: Memory and thinking tests, EKGs (a look at your heart rhythms), and MRI scans (a picture of your brain that shows changes related to AD).

For more information or to volunteer, please contact:

University of Kentucky
Sanders-Brown Center on Aging Clinic

Phone: (859) 323-1331

www.VIVA-MIND.org